Amgen's $600M R&D Expansion Boosts Shares 1.26% as Trading Volume Hits 157th Market Rank

, , ranking 157th in the market. , California, set to expand its R&D infrastructure and create hundreds of U.S. jobs. The facility will serve as a hub for innovation, supporting the development of therapies across oncology, cardiovascular disease, and other therapeutic areas.

The company is scheduled to present at the 23rd Annual Global Healthcare Conference on September 4, highlighting its strategic priorities and pipeline advancements. , reflecting a consistent history of dividend growth that appeals to income-focused investors. Recent regulatory updates, , reinforce its therapeutic portfolio’s strength.

Amgen’s stock performance has lagged the S&P 500 year-to-date, . Analysts remain optimistic about its long-term potential, driven by its robust R&D pipeline and market leadership in key therapeutic categories. The firm’s recent collaboration with , , further diversifies its revenue streams.

To deliver an accurate back-test, confirm the following parameters: (1) universe scope (U.S. listed stocks), (2) ranking by daily dollar volume, (3) equal-weight allocation for top 500 names, (4) zero transaction costs, and (5) benchmark comparison to SPY. These details will ensure the study aligns with the specified methodology.